Background: Previous evidence demonstrated that restoration of wild type VHL in human renal cancer cells decreased in vitro NK susceptibility. To investigate on the role of tumoral VHL status versus NK capability in renal cancer patients, 51 RCC patients were characterized for VHL mutational status and NK function.
Background
Renal cell carcinoma (RCC) is the most common kidney tumor in adults. Annually~295,000 new kidney cancer cases are diagnosed and~134,000 deaths are recorded worldwide [1, 2] . The most common histotype is clear cell-RCC (ccRCC) (70-80%) of which 50-70% carry Von Hippel-Lindau (VHL) gene mutations (VHL promoter hyper methylation and biallelic VHL inactivation) [3] [4] [5] [6] . The VHL protein (pVHL) functions as an E3 ubiquitin ligase that targets the hypoxia-inducible factors (HIFs) for ubiquitin-mediated degradation via the proteasome [7] [8] [9] . Although VHL plays a key role in RCC pathogenesis, the prognostic meaning of VHL mutations is controversial. VHL mutations were reported not to affect prognosis [10, 11] or to improving it [12] . Natural killer cells (NKs) are effectors of the innate immune response [13] activated by a net between inhibitory and activating receptors: human activating receptors comprise the natural cytotoxicity receptors (NCRs: NKp46, NKp30, and NKp44), C-type lectin receptors (CD94/NKG2C, NKG2D, NKG2E/ H, and NKG2F), and killer cell immunoglobulin-like receptors (KIRs) (KIR-2DS and KIR-3DS). Inhibitory receptors are C-type lectin receptors (CLRs) and KIRs (KIR-2DL and KIR-3DL) [14] . Certain VHL mutations correlate with low expression of classical HLA-I molecules and HLA-E expression that determine higher NK susceptibility reducing the engagement of KIR and NKG2A inhibitory receptors, respectively. Nevertheless multiple mechanisms concur in determining the NK sensitivity of cancer cells such as NK receptors surface ligands, LFA-1/ICAM-1 and HLA-I/NKR interactions, HLA-E molecules, soluble MICA A-B ligands, HLA-G, TGF beta secretion [15] . Moreover mechanisms affecting NK sensitivity may regulate gene transcription such as autophagy genes [16] .
T regulatory cells (Tregs) partecipate in the control of tumor immunity attenuating antitumor immune response [17] . Increase in peripheral and tumoral Tregs were observed in several cancers and inversely correlated to NKs number and function [18] . Tregs mainly regulate NK activity in a transforming growth factor-beta (TGF-β)-dependent manner. Soluble and membrane-bound TGF-β on regulatory T cells impaired NK cytolytic activity through down-regulation of NKG2D receptor on the NK cells [19] .
To investigate on the role of tumoral VHL status versus NK capability in renal cancer patients, 51 RCC patients were characterized for VHL mutational status and NK cytolytic activity toward A498-VHL-MUT and CAKI-1-VHL-WT human renal cancer cells.
Materials and methods

Patients and samples
Fifty five patients with primary RCC (41 clear cell; 4 papillary; 5 cromophobe; 5 unknown) and twelve healthy donors (HD) were enrolled in the study. The patients underwent surgery as part of their standard treatment at the Department of Urology, National Cancer Institute "G. Pascale" (Naples, Italy) and Genitourinary Oncology and Rare Cancer Center, Federico II University (Naples, Italy). RCC tumor and peritumoral tissues were obtained immediately after surgical resection, stabilized in RNA later (Qiagen) and stored at − 80°C. The distance of 1 cm was the minimal distance between tumor and normal-appearing renal tissue sampled. Informed consent from each patient was sought. The research protocol was approved by Human Ethical Committee of Institute (n. CEI/423/13).
Cell culture
The human renal cancer cell lines CAKI-1 (HLA-A*23:01/ A*24:02; HLA-B*35:02/B*44:03; HLA-C*04/C*04new) and SN12C (HLA-A*03/A*24new; HLA-B*07/B*44; HLA-C*05/C*07:02) VHL wild-type (VHL-WT), A498 (HLA-A *02:01; HLA-B*08:01; HLA-C*07) and 786-O (HLA-A*03:01; HLA-B*07/B*44, HLA-C*05/C*07:02) VHL mutated (VHL-MUT) and the human leukemic cell line K562 were obtained from the NCI 60 cancer cell line collection [20, 21] . All cells were cultured in the recommended growth medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% L-glutamine, 1% penicillin/ streptomycin and maintained in 95% air 5% CO 2 at 37°C.
VHL somatic mutational status
VHL mutational status was determined by PCR amplification and direct sequencing. DNA was extracted from primary tumor tissues using Nucleon Genomic DNA extraction Kit (GE Healthcare). The three VHL coding exons, with exon-intron junctions, were PCR amplified using the following primers: exon 1, 5′-agcgcgttcc atcctctac-3′ (forward) and 5′-agttccccgtctgcaaaat-3′ (reverse); exon 2, 5′-aggacggtcttgatctcctg-3′ (forward) and 5′-gcccaaagtgcttttgagac-3′ (reverse); exon 3, 5′-ttgttggca aagcctcttgt-3′ (forward) and 5′-tgcccctaaacatcacaatg-3′ (reverse). The thermal cycler (Applied Biosystems® 2720 Thermal Cycler) was programmed to first incubate the sample for 10 min for 95°C followed by 35 cycles consisting of 95°C for 45 s, 56°C (exon1 and 3) and 60°C (exon 2) for 45 s with final extension for 7 min at 72°C. Purified PCR products were then sequenced by using the Big Dye terminators version 3.1 cycle sequencing kit (Applied Biosystems, Courtaboeuf, France) and the 3130 Genetic Analyzer (Applied Biosystems). 
Flow cytometry
CD107a degranulation assay and IFN-γ production
Lysosome-associated membrane protein LAMP-1 (CD107a) is a marker of NK-cell degranulation. CD107a expression was measured by flow cytometry as previously described [23, 24] . Briefly, 1 ml whole blood was diluted with one volume RPMI-1640 containing 10% heat-inactivated fetal bovine serum and incubated with IL-2 (100 U/ml) overnight at 37°C, 5% CO 2 . The cytotoxic activity of NK cells was tested against NK-sensitive cell line K562 (HLA class I-negative) [25] , − NK. For intracellular staining of IFN-γ, 200 μl of IL-2 preactivated blood samples were incubated with 2 × 10 5 K562 or RCC target cells for 6 h at 37°C in a humidified 5% CO 2 incubator. The secretion inhibitor Brefeldin A (Sigma-Aldrich, Seelze, Germany) was added to the assay medium at a concentration of 10 μg/ml during the 6 h coincubation. After incubation, samples were placed on ice and stained with anti-CD56 and anti-CD3 mAbs, followed by erythrocyte lysis of blood samples with FACS Lysing Solution (BD Biosciences). Thereafter, cells were permeabilized using FACS permeabilizing solution (Perm2, BD Biosciences) and stained for intracellular IFN-γ with a PE-anti-IFN-γ antibody. Analysis was performed on a FACSAria II Cell Sorter 8-colour flow cytometer, blinded to patients' clinical characteristics.
Real-time PCR
RNA was isolated from tumoral and peritumoral RCC tissues using the RNeasy Mini kit (Qiagen, Hilden, Germany), according to manufacturer's instructions. cDNA was synthesized from 1 μg of total RNA using SuperScript III Reverse Transciptase (Invitrogen). Quantitative real-time PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) and data were collected and quantitatively analyzed on an ABI Prism 7000 System (Applied Biosystems). Primers sequences for NCAM-1, FCGR3a (CD16), DNAM-1, NKG2D, NKp46, NKp44, NKp30,KLRB1 and TGFB1 are detailed in Additional file 1: Table S1 . Relative mRNA expression was normalized with GUSB gene expression.
Immunohistochemistry (IHC)
Paraffin-embedded RCC tissue blocks, after heat induced epitope retrieval with citrate buffer (pH 6), were incubated overnight at 4°C with the mouse monoclonal IgG2B, anti-human NKp46 antibody, Clone 195,314 (MAB1850 R&D Systems) diluted 1:50, followed by incubation with peroxidase-conjugated secondary antibodies according to the manufacturer's instructions (EnVision+System, Dako North America, Inc., Carpinteria, CA). The NKp46 receptor demonstrates a high degree of lineage-specificity, being expressed almost exclusively in natural killer cells. . Five randomly selected areas were identified across the entire section from the center to the invasive margin (100× magnification). NKp46 + cells were counted in 5 consecutive non-overlapping high-power fields (HPF) 400x magnification (0.237 mm 
Statistical analysis
Statistical analysis were performed using the MedCalc 9.3.7.0 and Excel software. Unpaired Student t test or non-parametrical Mann-Whitney test was conducted. Statistical tests of hypotheses was two-sided with p < 0.05 taken as the criterion for statistical significance.
Results
RCC-VHL mutations were detected in 47% of RCC patients
Clinical pathological features of patients are summarized in Table 1 . The VHL status was assessed in 55 primary renal cancers by direct sequencing. As shown in Tables 1  and 2 , VHL was mutated in 26/55 (47%) cases, with missense mutations in 7/26 (27%), nonsense in 3/26 (12%), splice site in 2/26 (7%), frameshift deletions in 11/26 (42%) and frameshift insertions in 3/26 (12%) cases. The mutations exon prevalence was: exon 1, 50%; exon 2, 30.7%; and exon 3, 19.3%. VHL-MUT-RCC patients whole blood cytotoxicity was more efficient toward A498-VHL-MUT than CAKI-1-VHL-WT cells IL-2 activated whole-blood-NK derived cytotoxicity (as CD107a externalization and intracellular IFNγ production) was evaluated in 51 available RCC patients (28 VHL-WT and 23 VHL-MUT) and 12 healthy donors (HD). IL-2 activated whole-blood samples were co-cultured with target cells K562, A498-VHL-MUT (containing a 4-nt deletion at nt 639-642 in VHL exon 2) [26] and CAKI-1-VHL-WT cell lines. As reported in Additional file 2: Figure S1 the target cells K562 are MHC-I negative, while A498 and CAKI-1 cell lines express high levels of MHC-I molecules (81 and 86.2% respectively). In Fig. 1 NKs from HD (A) and RCC patients, either VHL-WT (B) or -MUT (C), displayed comparable externalization of CD107a against K562 cells (average CD107a + NK cells: 15 ± 0.02% vs 15 ± 3% vs 17 ± 2.5% respectively); absence of CD107a + NK cells activity was Clinical-pathological features and the CD107a assay results from single patient were shown in Additional file 3: Table S2 (VHL-MUT-RCC patients) and Additional file 4: Table S3 (VHL-WT-RCC patients). NK derived-IFN-γ was evaluated in 8 HD (Fig. 1D) 
VHL-MUT-RCC are NKp46
+ cells infiltrated and express NK activator receptors
With the intent to correlate peripheral and tumoral NK status, NK cell infiltration was analyzed on paraffin-embedded primary RCC tissues by immunohistochemical staining using the NK cell-specific marker NKp46. 23 RCC-patients, 15/23 (65.2%) VHL-MUT and 8/23 (34.8%) VHL-WT were evaluated for the expression of NKp46 + cells. Although RCCs generally display low NK cell infiltration [27] , NKp46 was expressed in the cytosol and on cell surface in lymphocytes (Fig. 3A) . In VHL-WT-RCC the NKp46 NKs function is regulated by activating receptors other than NKp46 that include NKp30, NKp44, C-type lectin receptors NKG2D, CD94/NKG2C, FcγRIIIa (CD16), activator KIRs, DNAX accessory molecule-1 (DNAM-1, CD226), Figure  S3 ). In addition, NKp30, NKp44, NKp46 and FcγRIIIIa mRNA were highly expressed in VHL-MUT tumors as compared to surrounding unaffected tissue (Additional file 2: Figure S4A ) while in the VHL-WT tumors no significant difference was retrieved (Additional file 2: Figure S4B ). Thus VHL-MUT tumors were characterized by high density of NKp46 + cells infiltration and high expression of NK activating genes such as NKp30, NKp46, NKp44 and DNAM-1.
VHL-MUT-RCC tumors display less functional Tregs
Since Tregs are supposed to suppress NK activity tumoral, Tregs (tTreg) identified as CD4 
Discussion
In the present study RCC-VHL mutational status was correlated to patients NK cytotoxicity through ex vivo evaluation toward human renal cancer cell lines A498
VHL-MUT and CAKI-1-VHL-WT. In 51 RCC patients (23 VHL-MUT and 28 VHL-WT) enhanced NK cell cytotoxicity, as CD107a expression in whole blood, was reported versus VHL-MUT A498 cells in VHL-MUT RCC patients. Moreover, in an autologous setting, IL-2 activated NKs isolated from RCC-VHL-MUT patients more efficiently degranulated toward RCC autologous tumor cells or A498 VHL-MUT cells as compared to SN12C (RCC-VHL-WT) cell line. Higher NK susceptibility was previously reported to correlate with decreased MHC Class I expression in cancer cells [30] . [31, 32] . These differences might accomplish for different phenotypes affecting NK sensitivity [15] .
Nowadays the effects of VHL mutations on NK activity is controversial. Previous evidence demonstrated that restoration of wild type VHL in human renal cancer cells decreased their NK susceptibility [33] while VHL mutations increased resistance to NK-mediated lysis through EPAS1/HIF-2α stabilization [16, 34] . NK cells induced a contact-dependent autophagy in ccRCC cells that was mediated by the HIF-2a targeted, inositol triphosphate receptor1 (ITPR1) in tumor cells. Blocking ITPR1 expression in ccRCC cells inhibited NK cell-induced autophagy and suppressed ccRCC resistance to NK cells [35] .
In our study blood derived from patients carrying RCC-VHL-MUT tumors display better NK susceptibility toward human renal cancer cells VHL-MUT suggesting an improvement in the innate immune response toward RCC.
To further correlate peripheral and tumoral NK status, NK cell infiltration was analyzed through the evaluation of NKp46 + cells and the NKs activating receptors NKp30, NKp44, NKp46, NKG2D, DNAM-1, NCAM-1 and FcγRIIIa. NK cell-activating ligands expression on A498 and CAKI-1 cells was recently reported [27] [28] [29] . Although a significant increase in NKG2D+ cells was not detected in our tested cells, A498 and CAKI-1 express high levels of DNAM-1 ligand PVR (94.8 and 99.1% respectively, Additional file 2: Figure S5 ). Previous authors stated that VHL-mutational status may not affect the expression of ligands for NKG2D and DNAM-1 activating NK receptors [33] . Higher infiltration of NKp46 + cells and increased expression of NKp30 and NKp46 [36] [37] [38] were detected in VHL-MUT-RCC compared to VHL-WT-RCC. Although the NKp46 receptor demonstrates a high degree of lineagespecificity, being expressed almost exclusively in natural killer cells [39] the presence of a rare NKp46 + CD3
+ population was reported. These include rare subsets of T cells (αβ and δγ) in humans and mice and a subset of group 3 innate lymphoid cells (ILCs) (NCR + ILC3) [36, 40] . Also DNAM1 or NKG2D may be expressed by T cells [36, 40, 41] . This is a limit of the present study. However the concomitant expression of NKp46 plus NKp30, NKp44 and DNAM-1 strongly suggest the hypothesis that NKs are involved.
To better define the role of NK cells in RCC tumors, Tregs and NKs are currently evaluated within the study REVOLUTION aimed at identify biomarkers of the checkpoint inhibitor nivolumab efficacy in metastatic renal cancer patients. Preliminary evidence showed that while the absolute value of CD3 − CD56 dim was not affected by nivolumab treatment NK cytotoxicity correlated with the responsiveness to treatment (Proceedings AACR 2017: Abstract #580).
Tregs suppress NK cell effector functions [42] impairing TGF-β pathway which, among other effects, induces downregulation of the activating NK cell receptor NKG2D [43] . Herein we report high infiltration of NKp46 + cells and reduced CD4 + CD25 hi Foxp3 + T cells in VHL-MUT-RCC tumors, although the reduction of TGF-β levels did not correspond to increased expression of NKG2D gene in VHL-MUT-RCC tumors. As in our results, Shen showed no significant correlation between peripheral Tregs and NKG2D expression in colorectal cancer patients NK cells [44] . Since VHL mutations induces PD-L1 expression in RCC, NK function may be a crucial element in nivolumab sensitivity [45] . NKs isolated from renal carcinoma patients expressed PD-1 on their surface and engagement of PD-1 signaling reduced their cytolytic potential. Treatment of patient-derived PD-1 + NK cells with an anti-PD-1 antibody (pidilizumab, CT-011) increased NK killing of autologous cancer cells in vitro [46] . NK cells also engage antibody-dependent cell mediated cytotoxicity (ADCC) and ex vivo treatment with the anti-CTLA4 ipilimumab enhances cetuximabmediated ADCC targeting CTLA-4 + Treg in head and neck squamous cell cancer (SCCHN) [47, 48] . Nowadays the immune checkpoint targeting agents nivolumab and ipilimumab represent a clinical standard for mRCC. Nevertheless tyrosine kinase inhibitors (TKI) still play a central role in metastatic RCC treament [49] and modify the tumor immune sensitivity. TKIs affect the frequency and composition of tumor immune cell subpopulations including Tregs, myeloid-derived suppressor cells as well as T and NK cells [50] [51] [52] . Sorafenib significantly reduce NKs activity against the RCC cell lines A498, ACHN and CAKI-2 [53] while axitinib promotes NK cell recognition and degranulation toward A498 RCC cells in a ROS-dependent manner [28] .
Conclusions
VHL tumoral mutations improve the NKs effectiveness in RCC patients and thus need to be considered in the evaluation of TKIs or immune based therapies. Moreover therapeutic strategies designed to target NK cells could be beneficial in VHL-mutated-RCCs alone or in association with immune checkpoints inhibitors.
Additional files
Additional file 1: Table S1 : Primer sequences for SYBR Green RT-qPCR. 
